Medivir Invites to Telephone Conference Today

Huddinge, SWEDEN

HUDDINGE, Sweden, July 15, 2003 (PRIMEZONE) -- Medivir will host a teleconference on 15 July at 13.00 SE time. Lars Adlersson CEO, Johan Harmenberg VP Pharmaceutical Development and Rein Piir CFO/IR, will present and comment on the Boehringer Ingelheim licensing agreement.

To participate please dial +44 (0) 20 7162 0184, code Medivir. The teleconference will be recorded and saved for 5 days. To reach the recorded version please dial +44 (0) 20 8288 4459 and use code 441 422 from 15.00 SE time.

For further information, please contact: Rein Piir, CFO/VP IR, Medivir, +46 8 5468 3100, +46 708 53 7292

The Medivir Group

Medivir is an innovative, specialist research corporation that develops new pharmaceutical compounds based on proteases and polymerases as target enzymes. The company is located in Huddinge, Sweden and Cambridge, UK.

The group comprised Medivir AB, the subsidiaries Medivir UK Ltd. and the CCS group until 1 July 2003, after this date the CCS group is owned by Segulah II L.P. Medivir has been quoted on the Stockholm Stock Exchange since 1996 and on the Attract40 list since 1 July 2003.

Medivir's research portfolio includes projects against HIV, jaundice, shingles, cold sores, osteoporosis, RA (rheumatoid arthritis), asthma and MS (multiple sclerosis).

Medivir has four projects in clinical development phases, two of which are entering phase III after completing phase II. One project is in phase I and one is in phase II.

In the first stage of preclinical pharmaceutical discovery, Medivir has some ten activities in explorative activities; the second, lead identification, encompasses three projects. The third stage, optimization, has one project, and two projects entering this stage. One project-MV026048-is in preclinical development, the stage closest to clinical development.

For additional information, please see Medivir's website

This information was brought to you by Waymaker

The following files are available for download: